- Home
- LENZ vs SDGR Comparison
LENZ vs SDGR Comparison
Compare LENZ & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- SDGR
- Stock Information
- Founded
- LENZ 2019
- SDGR 1990
- Country
- LENZ United States
- SDGR United States
- Employees
- LENZ N/A
- SDGR N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- SDGR Health Care
- Exchange
- LENZ Nasdaq
- SDGR Nasdaq
- Market Cap
- LENZ 1.2B
- SDGR 1.4B
- IPO Year
- LENZ 2021
- SDGR 2020
- Fundamental
- Price
- LENZ $31.84
- SDGR $22.61
- Analyst Decision
- LENZ Strong Buy
- SDGR Buy
- Analyst Count
- LENZ 4
- SDGR 8
- Target Price
- LENZ $56.25
- SDGR $26.75
- AVG Volume (30 Days)
- LENZ 1.2M
- SDGR 1.2M
- Earning Date
- LENZ 11-05-2025
- SDGR 11-05-2025
- Dividend Yield
- LENZ N/A
- SDGR N/A
- EPS Growth
- LENZ N/A
- SDGR N/A
- EPS
- LENZ N/A
- SDGR N/A
- Revenue
- LENZ $5,000,000.00
- SDGR $237,917,000.00
- Revenue This Year
- LENZ N/A
- SDGR $22.73
- Revenue Next Year
- LENZ $285.82
- SDGR $19.85
- P/E Ratio
- LENZ N/A
- SDGR N/A
- Revenue Growth
- LENZ N/A
- SDGR 18.59
- 52 Week Low
- LENZ $16.54
- SDGR $16.60
- 52 Week High
- LENZ $50.40
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- LENZ 33.24
- SDGR 61.37
- Support Level
- LENZ $30.66
- SDGR $19.99
- Resistance Level
- LENZ $42.98
- SDGR $22.32
- Average True Range (ATR)
- LENZ 3.10
- SDGR 1.18
- MACD
- LENZ -1.51
- SDGR 0.21
- Stochastic Oscillator
- LENZ 7.69
- SDGR 96.18
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.